Navigation Links
The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer
Date:6/2/2008

CINCINNATI, June 2 /PRNewswire/ -- The International Rett Syndrome Foundation announced today that Antony Horton Ph.D. will join the Foundation as Chief Scientific Officer, beginning July 1. Dr. Horton will oversee the foundation's research portfolio and its network of Rett Clinics, a series of clinics throughout the US with established neuromedical research and treatment centers. In addition, Dr. Horton will assist the IRSF Board of Directors in growing its funding pool and broadening its network of research partners. IRSF is the world's leading private funder of basic and clinical Rett syndrome research. IRSF was formed in 2007 by the merger of The International Rett Syndrome Association and the Rett Syndrome Research Foundation.

"Dr. Horton joins us during an exciting time for Rett syndrome research since recent breakthroughs give new insight into the function of the MECP2 gene that causes Rett syndrome and last year's discovery of the reversibility of Rett symptoms in mice models," said Kathryn Kissam, IRSF Board Chair. "We have the opportunity to fund crucial new research with the potential to impact lives and advance the understanding of Rett syndrome and related disorders. Dr. Horton's knowledge of the science of drug discovery and his experience in research program management will help the Foundation to shape and advance our mission of improving the lives of children living with Rett while searching for a cure to this devastating disease."

According to Dr. Horton, "As Chief Scientific Officer, I am eager to bring my scientific vision and research management experience to bear on the IRSF mission. I look forward to developing a portfolio of research programs that will accelerate translation of research discoveries into therapies to treat and cure Rett syndrome."

Dr. Horton earned his Ph.D. in developmental neurobiology at St. Andrew's University in Scotland. Currently, Dr. Horton is the Director of Scientific Affairs for the Alzhei
'/>"/>

SOURCE The International Rett Syndrome Foundation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2008)... Dr. Alan Greene from the kids, health w...eating only organic food. It,s the same benchmark ...nic. , Danville, CA (PRWE...certified organic by the Department of Agriculture... Alan Greene, why not people?, , , , ,In an artic...
(Date:12/4/2008)...a, Dec. 5 Health Care ...ay launched a global partnership to substitute mer...d affordable alternatives. , , The announce...nference on Alternatives to Mercury in Health Care...the Indian NGO Toxics Link. , , "This initi...
(Date:12/4/2008)...omen using Carraguard had no decrease in infection...lthDay News) -- A microbicidal vaginal gel called ...n. , That,s the conclusion of a study that incl... women at three sites in South Africa. , The wo...and told to use one applicator of gel and a condom...
(Date:12/4/2008)..., Dec. 4 MiddleBrook,Ph...nced that it has opened its,administrative and sa...antown,facility will continue to house certain pe...search and development group. The newly leased 14... house up to 60 employees as MiddleBrook,grows. ,...
Breaking Medicine News(10 mins):Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 2Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 3Health News:Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices 2Health News:Experimental Vaginal Gel Doesn't Ward Off HIV 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4
...here are certain conditions under which they loose... proteins leading to protein aggregation called as...e for causing neurodegenerative disorders such as ...am from Universitat Autònoma de Barcelona, led by ...
...be effectively fused with other cells to work else...ng to a study.// Researchers at Oregon Health and ...cells may be useful in fighting disease. The rese...Grompe, showed that mice with a disease called tyr...
...Wednesday doctors and hospitals in the global heal...Rs 100 million.// Six hospitals in Chennai, two in... residences of 14 prominent doctors were raided by...Rs.6 million in cash as well as fixed deposits and...
...e responsible for transferring the amino acid Cyst...ucing oxidative stress as Cysteine present in glut...nging activity in brain.// Free radicals are respo...y antioxidants. Professor Raymond Swanson and his ...
Other Medicine News:
(Date:12/3/2008)... potential in newly diagnosed patients with a life...o oral sessions at ASH , , - Exjade results...d patients by significantly reducing toxic iron th...m data from major independent breast cancer trial ...nt strategy, Femara vs. tamoxifen , , - Mul...
(Date:12/3/2008)...irstCall/ -- Wyeth Pharmaceuticals,a division of... submitted a,marketing authorization application ... approval to market its investigational 13-valent ...s and young children. Wyeth is seeking an,indica...D) caused by the 13,serotypes included in the inv...
(Date:12/2/2008)... -- Researchers using functional,MRI (fMRI) have ...rain,responsible for suppressing memory is dysfun... psychiatric disorders. Results of the study will ...adiological Society of North America,(RSNA). , ... stress-related disorders,traumatic memories are...
(Date:12/2/2008)...rizon Therapeutics, Inc., a,privately held biopha...tal,Phase 3 trials evaluating its lead investigat... endpoints. HZT-501, a novel, proprietary fixed-do...amotidine, demonstrated a,statistically significa...ti-inflammatory drug (NSAID)-induced upper gastroi...
Breaking Medicine Technology:More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference 8642 1Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 27859 1Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 27859 2LCA Vision Reports Third Quarter 2008 Financial Results 27857 1LCA Vision Reports Third Quarter 2008 Financial Results 27857 2LCA Vision Reports Third Quarter 2008 Financial Results 27857 3LCA Vision Reports Third Quarter 2008 Financial Results 27857 4LCA Vision Reports Third Quarter 2008 Financial Results 27857 5LCA Vision Reports Third Quarter 2008 Financial Results 27857 6LCA Vision Reports Third Quarter 2008 Financial Results 27857 7LCA Vision Reports Third Quarter 2008 Financial Results 27857 8LCA Vision Reports Third Quarter 2008 Financial Results 27857 9LCA Vision Reports Third Quarter 2008 Financial Results 27857 10LCA Vision Reports Third Quarter 2008 Financial Results 27857 11LCA Vision Reports Third Quarter 2008 Financial Results 27857 12LCA Vision Reports Third Quarter 2008 Financial Results 27857 13Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 1Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 2Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 3
...ON, March 06, 2007 /PRNewswire/ -- Up to two milli...p to 600,000,hospitalized. Its primary complicatio...ives annually -- more than breast cancer and,AIDS ...sease may be,at increased risk for DVT, because th...clots and pooling. Respiratory tract infection,may...
...E, Mass., March 06, 2007 /PRNewswire-FirstCall/ --... three completed,Phase III multi- center clinical ...acement therapeutic will be presented during,the N...al Meetings,taking place April 10th through 14th i...a are scheduled to be presented on,Wednesday, Apri...
Other Medicine Technology:DVT Awareness Survey Findings: Heart and Respiratory Patients 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4
The Estradiol (E2) Enzyme Immunoassay is intended for the for the quantitative determination of Estradiol (E2) concentration in human serum or plasma.
RIA kit for the quantitative determination of autoantibodies to thyroglobulin in serum.
...an 125I radioimmunoassay designed for,in vitro d... estradiol in serum, for the,investigation of pr...n, and for the,differential diagnosis of amenorr...tion,induction with and without stimulation in,...
Coat-A-Count Estradiol is,a no-extraction, solid-phase 125I,radioimmunoassay designed for in vitro,diagnostic use in the quantitative,measurement of estradiol in serum, for the,differential
Medicine Products: